Humanigen to Present at Upcoming Investor Conferences
Humanigen, Inc. (Nasdaq: HGEN) announced management will present at the PNC Bank & Solebury Trout COVID Webinar and LD Micro Investor Conference on December 15, 2020. CEO Cameron Durrant will discuss company programs and provide updates on the Phase 3 clinical trial of lenzilumab for COVID-19 patients. The PNC webinar is scheduled from 12:00-1:00 PM EST, while the LD Micro conference presentation is from 2:20-2:40 PM EST. Humanigen focuses on therapies targeting cytokine storms to reduce severe lung dysfunction caused by SARS-CoV-2.
- None.
- None.
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced that the Company’s management will present at the PNC Bank & Solebury Trout COVID Webinar and LD Micro Investor Conference on December 15, 2020.
Cameron Durrant, MD, MBA, chief executive officer of Humanigen, will provide an overview of the Company’s programs and share an update on enrollment for its Phase 3 clinical trial of lenzilumab in patients hospitalized with COVID-19.
Details for the upcoming virtual investor conferences are below:
PNC Bank & Solebury Trout COVID Webinar (December 15, 2020)
Date: Tuesday, December 15, 2020
Topic: PNC Healthcare Family Office 1 Hour COVID Webinar
Presentation Time: 12:00-1:00 PM EST
Registration Link: https://soleburytrout.zoom.us/webinar/register/WN_nuoXoYA5RgaE48ySN5Orxg
LD Micro Investor Conference (December 14-15, 2020)
Date: Tuesday, December 15, 2020
Panel Series: Track 3 – Research Rockstars
Presentation Time: 2:20-2:40 PM EST
Event Link: https://ve.mysequire.com/company?company_id=cad83061-5508-4a9a-8edf-9423f1bc869c
About Humanigen, Inc.
Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The company’s immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit www.humanigen.com.
Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory approvals and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005264/en/
FAQ
What is Humanigen's stock symbol and when will they present at the investor conferences?
Who will present for Humanigen at the December 15, 2020 conferences?
What will be discussed during Humanigen's presentation at the investor conferences?
What are the details of the PNC Bank & Solebury Trout COVID Webinar?
What is the focus of Humanigen’s research and development?
